BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 9108396)

  • 1. Human platelets as a model for the binding and degradation of thrombopoietin.
    Fielder PJ; Hass P; Nagel M; Stefanich E; Widmer R; Bennett GL; Keller GA; de Sauvage FJ; Eaton D
    Blood; 1997 Apr; 89(8):2782-8. PubMed ID: 9108396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets.
    Fielder PJ; Gurney AL; Stefanich E; Marian M; Moore MW; Carver-Moore K; de Sauvage FJ
    Blood; 1996 Mar; 87(6):2154-61. PubMed ID: 8630374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics.
    Li J; Xia Y; Kuter DJ
    Br J Haematol; 1999 Aug; 106(2):345-56. PubMed ID: 10460590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human platelets display high-affinity receptors for thrombopoietin.
    Broudy VC; Lin NL; Sabath DF; Papayannopoulou T; Kaushansky K
    Blood; 1997 Mar; 89(6):1896-904. PubMed ID: 9058709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia.
    Li J; Xia Y; Kuter DJ
    Br J Haematol; 2000 Dec; 111(3):943-53. PubMed ID: 11122159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human plasma thrombopoietin levels are regulated by binding to platelet thrombopoietin receptors in vivo.
    Scheding S; Bergmann M; Shimosaka A; Wolff P; Driessen C; Rathke G; Jaschonek K; Brugger W; Kanz L
    Transfusion; 2002 Mar; 42(3):321-7. PubMed ID: 11961237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of platelet activation in vitro by the c-Mpl ligand, thrombopoietin.
    Chen J; Herceg-Harjacek L; Groopman JE; Grabarek J
    Blood; 1995 Dec; 86(11):4054-62. PubMed ID: 7492761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelets release thrombopoietin (Tpo) upon activation: another regulatory loop in thrombocytopoiesis?
    Folman CC; Linthorst GE; van Mourik J; van Willigen G; de Jonge E; Levi M; de Haas M; von dem Borne AE
    Thromb Haemost; 2000 Jun; 83(6):923-30. PubMed ID: 10896250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia.
    Horikawa Y; Matsumura I; Hashimoto K; Shiraga M; Kosugi S; Tadokoro S; Kato T; Miyazaki H; Tomiyama Y; Kurata Y; Matsuzawa Y; Kanakura Y
    Blood; 1997 Nov; 90(10):4031-8. PubMed ID: 9354672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study of thrombopoietin and its receptor C-mpl in acute leukemia].
    Guo Y; Bian S; Luo M
    Zhonghua Xue Ye Xue Za Zhi; 1999 Mar; 20(3):120-3. PubMed ID: 11601235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine 462 of the membrane-proximal F'-G' loop of murine Mpl is not essential for high-affinity binding of thrombopoietin.
    Sabath DF; Lin N; Sabath DE; Kaushansky K; Broudy VC
    Cytokine; 2000 Feb; 12(2):127-33. PubMed ID: 10671297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Normal platelets and megakaryocytes are produced in vivo in the absence of thrombopoietin.
    Bunting S; Widmer R; Lipari T; Rangell L; Steinmetz H; Carver-Moore K; Moore MW; Keller GA; de Sauvage FJ
    Blood; 1997 Nov; 90(9):3423-9. PubMed ID: 9345025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralization of biological activity and inhibition of receptor binding by antibodies against human thrombopoietin.
    Tahara T; Kuwaki T; Matsumoto A; Morita H; Watarai H; Inagaki Y; Ohashi H; Ogami K; Miyazaki H; Kato T
    Stem Cells; 1998; 16(1):54-60. PubMed ID: 9474748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-level expression of Mpl in platelets and megakaryocytes is independent of thrombopoietin.
    Cohen-Solal K; Vitrat N; Titeux M; Vainchenker W; Wendling F
    Blood; 1999 May; 93(9):2859-66. PubMed ID: 10216080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism of thrombopoietin (TPO) in vivo: determination of the binding dynamics for TPO in mice.
    Stefanich E; Senn T; Widmer R; Fratino C; Keller GA; Fielder PJ
    Blood; 1997 Jun; 89(11):4063-70. PubMed ID: 9166846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombopoietin in vitro and in vivo.
    Alexander WS; Begley CG
    Cytokines Cell Mol Ther; 1998 Mar; 4(1):25-34. PubMed ID: 9557214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelets exposed to elevated levels of endogenous thrombopoietin in vivo have a reduced response to megakaryocyte growth and development factor in vitro.
    Nishiyama U; Morita H; Torii Y; Kuwaki T; Shimizu E; Akahori H; Kato T; Miyazaki H
    Thromb Haemost; 2001 Jan; 85(1):152-9. PubMed ID: 11204567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl.
    Broudy VC; Lin NL
    Cytokine; 2004 Jan; 25(2):52-60. PubMed ID: 14693160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombocytopenia in c-mpl-deficient mice.
    Gurney AL; Carver-Moore K; de Sauvage FJ; Moore MW
    Science; 1994 Sep; 265(5177):1445-7. PubMed ID: 8073287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of the receptor MPL and proliferative effects of its ligand thrombopoietin on human leukemia cells.
    Quentmeier H; Zaborski M; Graf G; Ludwig WD; Drexler HG
    Leukemia; 1996 Feb; 10(2):297-310. PubMed ID: 8637239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.